Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rSIFN-co Nasal Spray for COVID-19 Prevention and Treatment
NCT05485584Phase 2Completed
- Sponsor
- Sichuan Huiyang Life Engineering
- Start
- Jul 2022
- Primary completion
- Apr 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant super-compound interferon in coronavirus disease 2019 (COVID-19), sponsored by Sichuan Huiyang Life Engineering. Started Jul 2022; status: completed.
02
Drugs
recombinant super-compound interferon
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05485584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485584.